Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Idalopirdine Commercial vs Clinical Tablets
NCT02894515Phase 1Withdrawn
- Sponsor
- Lundbeck
- Start
- Sep 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Idalopirdine in Alzheimer's disease (AD) (2 arms), sponsored by Lundbeck. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last quantifiable concentration and Maximum observed concentration. Planned start Sep 2016; status: withdrawn.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02894515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02894515.